Inflammatory Bowel Disease
Evaluate the probability of disease progression in a Crohn’s disease patient by providing a personal serogenetic profile.
PROMETHEUS® Crohn’s Prognostic combines serologic and genetic markers in an innovative blood test that quantifies a patient’s individual probability of developing disease complications over time. Serologic markers include ASCA IgA, ASCA IgG and priority markers anti-CBir1, anti-I2, anti-OMPC, and DNAse sensitive pANCA. Genetic markers include NOD2 variants (SNPS 8, 12, 13). The objective information from Crohn’s Prognostic may allow physicians to stratify patients, assist in optimizing management strategies and assist with risk/benefit healthcare provider/patient discussions.
Sample insurance correspondence for PROMETHEUS® Crohn’s Prognostic
References
Plevy, Silverberg, Lockton et al. Combined archaeology, genetic, and inflammatory markers differentiate non-IBD, Crohn’s Disease, and ulcerative colitis patients. Inflammatory Bowel Diseases. 2013; 19(6):1139-48.
Lichtenstein, Targan, Dubinsky et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn’s Disease behavior. Inflammatory Bowel Diseases. 2011; 17(12):2488-96.
Prometheus Laboratories is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical laboratory testing and is accredited by the College of American Pathologists (CAP). Tasso+ is a FDA Class II Lancet 510(k)-cleared single-use blood lancing device intended for obtaining microliter capillary whole blood samples that is manufactured by Tasso, Inc. PredictrPK and Anser sample collection with the Tasso+ device is not yet available for New York State patients. This material is provided for general information purposes only as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.